Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3–9-month intervals following two-dose inactivated vaccine (CoronaVac)

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

(2022) Jingxin Li et al.   NATURE MEDICINE

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant

(2022) Xin Zhao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022

(2022) Anastasia S. Lambrou et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine

(2022) Yihao Liu et al.   Cell Discovery

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults

(2022) Lianpan Dai et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

(2021) Shilong Yang et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

(2021) Xinxue Liu et al.   LANCET

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

(2021) Madhumita Shrotri et al.   LANCET

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

(2021) Alberto M Borobia et al.   LANCET

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

(2021) Alejandro Jara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

(2021) Jingwen Ai et al.   CELL RESEARCH

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

(2021) Gang Zeng et al.   LANCET INFECTIOUS DISEASES

The emergence, genomic diversity and global spread of SARS-CoV-2

(2021) Juan Li et al.   NATURE

Boosting immunity to COVID-19 vaccines

(2021) Jennifer A. Juno et al.   NATURE MEDICINE

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

(2020) Lianpan Dai et al.   CELL

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

(2020) Maheshi N Ramasamy et al.   LANCET